Shares of Aquestive Therapeutics Inc. AQST, -28.94% tumbled 28.4% in premarket trading on Tuesday after the company said Monday that the Food and Drug Administration is delaying the review of its still-investigational seizure treatment. The regulator was expected to announce its decision about whether to approve the therapy by Dec. 23; the FDA said in the notice that it is “currently unable to provide an estimate of the timing of an expected action.” The FDA is not requiring any additional information from Aquestive at this time. The company’s stock gained 16.2% so far this year, while the broader S&P 500 SPX, +0.75% is up 21.6%.
View Article Origin Here
